课题基金 / 基金详情

项目摘要

项目成果

Robert A Schnoll的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):治疗尼古丁依赖的新方法仍然是优先事项。经皮尼古丁贴片是最广泛使用的烟草依赖治疗形式,但使用这种治疗的吸烟者中只有约1/5实现戒烟。可能导致对经皮尼古丁反应不良的一个因素是尼古丁代谢速率的个体间差异,其可以通过唾液中3 '羟基可替宁(3-HC)与其前体可替宁的比率来测量。两项经皮尼古丁临床试验表明,3-HC/可替宁比值可预测经皮尼古丁的反应,因此尼古丁代谢较快者(3-HC/可替宁比值较高)的戒烟率较低,而尼古丁代谢较慢者的戒烟率较低。在这些试验中的戒烟者中,3- HC/可替宁比率还预测了经皮尼古丁的尼古丁治疗水平,尼古丁代谢较快的人表现出较低的尼古丁。因此,尼古丁代谢较快者可能需要更高的尼古丁剂量,才能从经皮尼古丁中获得与尼古丁代谢较慢者相同的治疗益处。迄今为止,临床试验表明,与标准剂量的经皮尼古丁(21 mg)相比,更高剂量(42 mg)对戒烟率没有显着影响。然而,没有高剂量尼古丁透皮试验考虑尼古丁代谢速率的个体间差异。因此,作为进行充分把握度的随机临床试验以评估尼古丁慢代谢者与快代谢者的标准与高剂量经皮尼古丁的初步步骤,我们首次提出评估高剂量经皮尼古丁(与标准剂量)在尼古丁快代谢者(即,3-HC/可替宁比率分布的上四分位数)。我们仅选择尼古丁快速代谢者进行本试验,因为:1)尼古丁缓慢代谢者在标准经皮尼古丁下表现出较高的戒烟率,并且可能会因较高剂量而出现不良反应; 2)作为“概念验证”R21应用,我们的主要目标是测试高剂量尼古丁是否会增加尼古丁快速代谢者的戒烟率。具体而言,100名尼古丁快速代谢的吸烟者将接受咨询,并随机接受:1)标准(1 × 21 mg贴剂和1 ×安慰剂贴剂)或2)高剂量(2 × 21 mg贴剂)经皮尼古丁。主要结局是治疗8周后经生化验证的7天点患病率停止。贴剂相关副作用和经皮尼古丁效应介质的差异(例如,尼古丁水平,戒断)。最终,这一系列研究希望提供必要的证据,将3-HC/可替宁比例的研究转化为治疗烟草依赖的临床实践。具体而言,本研究可能表明,尼古丁代谢率的测量可用于最大限度地提高经皮尼古丁的治疗获益,方法是为尼古丁的慢代谢者提供标准贴剂剂量,为尼古丁的快代谢者提供高剂量经皮尼古丁。确定一种有效的治疗尼古丁代谢较快的人也是至关重要的,因为这些人患肺癌的风险增加。 公共卫生相关性:不幸的是,我们仍然需要评估和确定帮助人们戒烟的新方法。人与人之间尼古丁代谢速度的差异会影响对尼古丁透皮贴剂(最流行的尼古丁依赖治疗)的反应,并影响治疗后尼古丁的血浆水平。这些研究表明,尼古丁的快速代谢者如果接受更高剂量的经皮尼古丁,可能会显示出更好的戒烟率。这项初步研究旨在首次评估尼古丁快速代谢者在给予高剂量经皮尼古丁时与标准剂量相比是否表现出更高的戒烟率。研究结果可能有助于支持后续的大型试验,以评估尼古丁慢代谢者与快代谢者的标准与高剂量经皮尼古丁,这可能导致使用尼古丁贴剂治疗尼古丁依赖的更个性化方法,以改善经皮尼古丁的治疗益处。
英文摘要
DESCRIPTION (provided by applicant): Novel approaches to treating nicotine dependence remain a priority. The transdermal nicotine patch is the most widely used form of tobacco dependence treatment, but only ~1 in 5 smokers who use this treatment achieve cessation. One factor that may contribute to a poor response to transdermal nicotine is inter-individual variability in the rate of nicotine metabolism, which can be measured in saliva by the ratio of 3'hydroxycotinine (3-HC) to its precursor cotinine. Two clinical trials with transdermal nicotine have shown that the 3-HC/cotinine ratio predicts response to transdermal nicotine such that faster metabolizers of nicotine (higher 3-HC/cotinine ratios) have lower quit rates, vs. slower nicotine metabolizers. Among abstainers in these trials, the 3- HC/cotinine ratio also predicts therapeutic levels of nicotine on transdermal nicotine, with faster metabolizers of nicotine exhibiting lower nicotine. Thus, faster metabolizers of nicotine may require higher nicotine doses to achieve the same therapeutic benefit from transdermal nicotine as do slow nicotine metabolizers. To date, clinical trials have shown that, compared to the standard dose of transdermal nicotine (21mg), higher doses (42mg) have no significant effect on quit rates. However, no trial of high dose transdermal nicotine considered inter-individual variability in the rate of nicotine metabolism. Thus, as a preliminary step toward conducting a fully-powered, randomized clinical trial to assess standard vs. high dose transdermal nicotine for slow vs. fast metabolizers of nicotine, we propose to evaluate, for the first time, the efficacy of high-dose transdermal nicotine (vs. standard dose) among fast metabolizers of nicotine (i.e., upper quartile of the 3-HC/cotinine ratio distribution). We chose only fast metabolizers of nicotine for this trial since: 1) slow metabolizers of nicotine exhibit high quit rates on standard transdermal nicotine and may experience adverse effects from higher doses; and 2) as a "proof of concept" R21 application, our primary objective is to test whether high doses of nicotine increase quit rates among fast metabolizers of nicotine. Specifically, 100 smokers who are fast metabolizers of nicotine will receive counseling and will be randomized to: 1) standard (1 X 21mg patch and 1 X placebo patch), or 2) high dose (2 x 21mg patches) transdermal nicotine. The primary outcome is biochemically-verified 7-day point prevalence cessation after 8 weeks of treatment. Differences in patch-related side effects and mediators of transdermal nicotine effects (e.g., nicotine levels, withdrawal) across the study conditions will also be assessed. Ultimately, this line of research hopes to provide the evidence necessary to translate research on the 3-HC/cotinine ratio to clinical practice for the treatment of tobacco dependence. Specifically, this research may show that a measure of nicotine metabolism rate could be used to maximize the therapeutic benefits of transdermal nicotine by providing slow metabolizers of nicotine with a standard patch dose and fast metabolizers of nicotine with high dose transdermal nicotine. Identifying an effective treatment for faster metabolizers of nicotine is also critical since these individuals are at increased risk for lung cancer. PUBLIC HEALTH RELEVANCE: Unfortunately, we still need to assess and identify novel ways to help people quit smoking. Differences between people in terms of how fast they metabolize nicotine influences response to transdermal nicotine patches, the most popular nicotine dependence treatment, and it affects plasma levels of nicotine from treatment. These studies suggest that fast metabolizers of nicotine may show better quit rates if they receive higher doses of transdermal nicotine. This preliminary study is designed to assess, for the first time, whether fast nicotine metabolizers show higher quit rates if given high dose transdermal nicotine, vs. standard dose. The study findings may help to support a subsequent large trial to assess standard vs. high dose transdermal nicotine for slow vs. fast metabolizers of nicotine, which may lead to a more personalized approach to treating nicotine dependence using the nicotine patch to improve therapeutic benefits of transdermal nicotine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Patient-Oriented Research Mentoring Program in Tobacco Dependence Research
  • 批准号:
    10094212
  • 项目类别:
  • 资助金额:
    $18.7万
  • 财政年份:
    2018
  • 负责人:
    Robert A Schnoll
  • 依托单位:
A Mentoring Program in Patient-Oriented Tobacco Dependence and Implementation Science Research
  • 批准号:
    10700361
  • 项目类别:
  • 资助金额:
    $19.75万
  • 财政年份:
    2018
  • 负责人:
    Robert A Schnoll
  • 依托单位:
A Patient-Oriented Research Mentoring Program in Tobacco Dependence Research
  • 批准号:
    10350574
  • 项目类别:
  • 资助金额:
    $18.7万
  • 财政年份:
    2018
  • 负责人:
    Robert A Schnoll
  • 依托单位:
Testing an Organizational Change Model to Address Smoking in Mental Healthcare
  • 批准号:
    9886075
  • 项目类别:
  • 资助金额:
    $63.77万
  • 财政年份:
    2016
  • 负责人:
    Robert A Schnoll
  • 依托单位:
海外基金